Vice President, Clinical Development, 

Parker Institute for Cancer Immunotherapy, United States of America

• Speaker, Cancer Immunotherapy Plenary, 22 Sep 2018

Dr Ramy Ibrahim, MD, is a recognised leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr Ibrahim currently serves as vice president of clinical development at the Parker Institute for Cancer Immunotherapy. As part of his role, he has built clinical trial management capabilities within the Institute that enables multi-centre clinical trials across the Parker centres to be conducted. His team is focused on supporting novel combinations that are science-driven and innovative. Throughout his career, Dr Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Friends of Cancer research, the Cancer Research Institute and Cancer Support Community (CSC). He is a trained medical oncologist, who has conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD, U.S.A.